What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
BMO Capital has upgraded its rating of Neurocrine Biosciences (NASDAQ:NBIX) to Market Perform with a new price target of $96.00, up from $91.00. Neurocrine Biosciences' shares are currently trading at $95.23, up 0.74% over the last 24 hours. A move to $96.00 would account for a 0.8% increase from the current share price.
July 06, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has upgraded its rating of Neurocrine Biosciences to Market Perform and raised its price target to $96.00. The company's shares are currently trading at $95.23.
The upgrade by BMO Capital is a positive signal for Neurocrine Biosciences. The new price target of $96.00, which is higher than the current trading price, suggests that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100